Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas.
暂无分享,去创建一个
Gouri Nanjangud | A. Olshen | A. Zelenetz | J. Teruya-Feldstein | E. Venkatraman | R. Chaganti | G. Nanjangud | J. Houldsworth | J. Halaas | S. Chaganti | Julie Teruya-Feldstein | Adam B Olshen | Jane Houldsworth | R S K Chaganti | Andrew D Zelenetz | Weiyi Chen | Seeta Chaganti | Ennapadem S Venkatraman | Jeffrey Halaas | Weiyi Chen
[1] H. Tagawa,et al. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma , 2004, Oncogene.
[2] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[3] A. López-Guillermo,et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] K. Offit,et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. , 1996, Blood.
[5] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[6] S. Lowe,et al. A microRNA polycistron as a potential human oncogene , 2005, Nature.
[7] J. Cigudosa,et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.
[8] L. Pasqualucci,et al. Expression of the AID protein in normal and neoplastic B cells. , 2004, Blood.
[9] D. Weisenburger,et al. Similar patterns of genomic alterations characterize primary mediastinal large‐B‐cell lymphoma and diffuse large‐B‐cell lymphoma , 2002, Genes, chromosomes & cancer.
[10] A. Zelenetz,et al. Molecular cytogenetic analysis of genomic instability at the 1q12–22 chromosomal site in B‐cell non‐Hodgkin lymphoma , 2002, Genes, chromosomes & cancer.
[11] A. Stoffel,et al. The p73 locus is commonly deleted in non-Hodgkin's lymphomas. , 2004, Leukemia research.
[12] J. Teruya-Feldstein,et al. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. , 2000, Seminars in hematology.
[13] H. Tagawa,et al. Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma , 2004, Cancer Research.
[14] J. Inazawa,et al. GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines , 2003, Journal of Human Genetics.
[15] S. Okamura,et al. Isolation and characterization of a novel TP53‐inducible gene, TP53TG3 , 1999, Genes, chromosomes & cancer.
[16] L. Feuk,et al. Detection of large-scale variation in the human genome , 2004, Nature Genetics.
[17] M. Minden,et al. Molecular cytogenetic characterization of non‐Hodgkin lymphoma cell lines , 2002, Genes, chromosomes & cancer.
[18] J. Teruya-Feldstein,et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. , 2002, Human pathology.
[19] H. Tagawa,et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.
[20] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[21] H. Döhner,et al. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. , 1998, Blood.
[22] D G Oscier,et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. , 2001, Blood.
[23] C. Perou,et al. Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.
[24] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[25] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[26] D. Cox. Regression Models and Life-Tables , 1972 .
[27] Hiroyuki Tagawa,et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. , 2004, Cancer research.
[28] Ash A. Alizadeh,et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.
[29] D. Weisenburger,et al. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[31] H. Kohlhammer,et al. Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization , 2003, Oncogene.
[32] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Golub,et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.
[34] Nallasivam Palanisamy,et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. , 2004, Blood.
[35] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[36] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.